1. Review the potential for modulation of non-glycaemic CV risk factors with SGLT-2 inhibitors

2. Determine the association between initiation of SGLT-2 therapy and HF or death in patients with and without CVD.



Session date: 
03/08/2019 - 7:30am to 8:30am CST
NorthShore - Evanston
Evanston, IL 60201
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Haseeb Saeed, MD